方法：2015-05/2016-03住院治疗的RVO病例122例122眼，按照随机数字表法随机分为研究组58例58眼(其中中央静脉阻塞患者24例24眼，分支静脉阻塞患者34例34眼)和对照组64例64眼(其中中央静脉阻塞患者26例26眼，分支静脉阻塞患者38例38眼)。两组患者行康柏西普玻璃体腔内注射术。研究组注射药物前行532激光治疗。治疗前及治疗后1、3、6mo复查行光学相干断层扫描(optical coherence tomography，OCT)检查，比较两组最佳矫正视力(best corrected visual acuity，BCVA)，黄斑中心凹厚度及视网膜色素上皮(RPE)隆起的面积。

结果：治疗后1、3、6mo两组的BCVA均较术前提高，具有统计学意义(P<0.05)； 治疗后3、6mo研究组BCVA提高均大于对照组，具有统计学意义(P<0.05)，1mo两组间差别无统计学意义。黄斑中心凹厚度及直径3mm²圆内RPE隆起的厚度均较术前减小，具有统计学意义(P<0.05)。对于黄斑中心凹厚度及直径3mm²圆内RPE隆起的厚度，研究组下降水平均大于对照组，治疗后3、6mo均具有统计学意义(P<0.05)，但治疗后1mo两组间的差别无统计学意义。所有患者均未出现不良反应。

结论：康柏西普注射可提高患者视力，降低黄斑中心凹厚度及RPE隆起的面积，与532激光合用对RVO效果较单纯药物注射更好。

METHODS: Totally 122 cases(122 eyes)checked in hospital for RVO were randomly divided into two groups by using the random number list during May 2015 to March 2016. The research group with 58 cases(58 eyes)comprised of 24 cases(24 eyes)diagnosed as central retinal vein occlusion and 34 cases(34 eyes)diagnosed as branch retinal vein occlusion. The control group with 64 cases(64 eyes)comprised of 26 cases(26 eyes)diagnosed as central retinal vein occlusion and 38 cases(38 eyes)diagnosed as branch retinal vein occlusion. All the cases were treated with intravitreal conbercept injections while the research group combined with treatment of received 532-laser retinal photocoagulation pre-injection. Optical coherence tomography(OCT)was adapted pre and 1,3 and 6mo after intravitreal injection. The best corrected visual acuity(BCVA), thickness of macular central concave and retinal pigment epithelium uplift area were compared between the two groups.

RESULTS: BCVA of all cases were increased 1, 3 and 6mo after treatment, and the difference had statistical significance(P<0.05). The research group had a better improvement of BCVA than control group, and there were significant differences between the two groups 3, 6mo after treatment but 1mo. Thickness of macular central concave and retinal pigment epithelium uplift area of two groups were decreased 1, 3 and 6mo after treatment, the difference had statistical significance(P<0.05). The research group had a bigger decrease value than the control group as for thickness of macular central concave and retinal pigment epithelium uplift area, there were significant differences between two groups 3, 6mo after treatment but 1mo. No adverse events occurred during the treatment.

CONCLUSION: Intraviteal conbercept injection can increase the visual acuity and decrease both the thickness of macular central concave and retinal pigment epithelium uplift area of patients with retinal vein occlusion. Combined with 532-laser retinal photocoagulation will achieve better outcome than intravitreal injection only.